ChLIA-based tests for detection of antibodies against Borrelia and Epstein-Barr Virus now available on EUROIMMUN RA Analyzer 10 System
Two new CE-marked chemiluminescence immunoassays (ChLIA) for the detection of anti-Borrelia (Lyme disease) and anti-EBV/EBNA (Epstein-Barr Virus) antibodies on the EUROIMMUN RA Analyzer 10 system are available now.
The system, used in conjunction with the ChLIA products, functions as a compact automation solution in small- to medium-sized laboratories, or complements high-throughput-devices in large-sized laboratories. Test- and lot-specific information, including stored standard curves, are imported into the database by means of an RFID code, enabling error-free and convenient loading, along with efficient and secure test evaluation.
The EUROIMMUN RA Analyzer 10 allows continuous loading—also as part of a testing line—to ensure every sample is processed with minimal effort and shorter reaction times as a single determination. The ChLIA technology further minimizes reaction times, with total analysis in 30 minutes or less. In addition, the preferred processing of emergency (STAT) samples gives laboratories with different requirements and sample volumes unparalleled flexibility in their laboratory routine.
“Lyme disease represents the most frequent tick-borne infection in the northern hemisphere, while EBV remains one of the most common human pathogens (herpesvirus 4) with a prevalence of up to 99%. Without treatment, Borrelia infections can lead to severe clinical symptoms. In case of EBV it is important to ensure early diagnosis due its high contagiousness,” said Wolfgang Schlumberger, Ph.D., CEO of EUROIMMUN, a PerkinElmer company. “By introducing assays for the RA Analyzer 10, we’ve extended our already comprehensive portfolio of serological assays for Lyme disease and EBV diagnostics.”